US Stock MarketDetailed Quotes
GANX Gain Therapeutics
- 1.070
- -0.270-20.15%
Close Aug 29 16:00 ET
- 1.031
- -0.039-3.67%
Post 18:17 ET
27.32MMarket Cap-816P/E (TTM)
1.340High1.030Low4.44MVolume1.330Open1.340Pre Close5.19MTurnover18.33%Turnover RatioLossP/E (Static)25.54MShares5.33052wk High2.32P/B25.93MFloat Cap0.89052wk Low--Dividend TTM24.23MShs Float17.930Historical High--Div YieldTTM23.13%Amplitude0.890Historical Low1.169Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Gain Therapeutics Stock Forum
2 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
Gain Therapeutics (Nasdaq: GANX) has announced positive topline results from its Phase 1 clinical trial of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson's disease.
The study, which enrolled 72 healthy volunteers, demonstrated that GT-02287 was safe and well-tolerated at a...
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Gain Therapeutics has presented data at the Federation of European Neuroscience Societies (FENS) Forum 2024 showing that their lead therapeutic candidate, GT-02287, has significantly improved cognitive function and activities of daily living in a preclinic...
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
Gain Therapeutics has announced that its late-breaking abstract on GT-02287, a clinical-stage GCase enhancer, has been accepted for presentation at the FENS Forum 2024 in Vienna. New data reveals improvements in cognitive performance in a preclinical model of GBA1 Parkinson’s disease. The presentation is sched...
No comment yet